ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
Key claim: A 12-week personalized aerobic and resistance exercise program is being evaluated for feasibility, safety, and efficacy in reducing fatigue and improving physical function and inflammatory biomarkers in MPN and CML patients.
Abstract
This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Although many patients achieve good disease control with modern therapies, they often experience persistent symptoms such as fatigue that significantly affect daily life.
Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. The program consists of two supervised sessions per week, along with additional home-based aerobic activity. Before and after the program, participants will undergo comprehensive assessments, including cardiopulmonary exercise testing, physical function tests, questionnaires on fatigue and quality of life, and blood sample collection.
The study aims to determine whether this type of exercise program is feasible and safe, and whether it can reduce fatigue and improve physical capacity, quality of life, and biological markers related to inflammation and metabolism. Participants will also be followed after the intervention to evaluate whether the benefits are maintained over time.
Why this matters
Fatigue is among the most disabling MPN symptoms, and lifestyle interventions for it have rested almost entirely on adjacent oncology data. ENERGIA is one of the first MPN-direct prospective exercise trials pairing symptom endpoints with inflammatory biomarkers, which could begin to convert exercise recommendations from mechanism-plausible to mpn-direct tier. Even as an early-phase feasibility study, it sets a template for tier-upgrade evidence in this area.